SEC Form 4 · accession 0001209191-18-034482
Viking Therapeutics, Inc. · VKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lawson Macartney
Director
Period of report
May 29, 2018
Accepted (ET)
May 31, 2018 · 6:57 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001607678
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock, par value $0.00001 per shareF1 | May 29, 2018 | P | 47,965 | $5.219 | A | 47,965 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.1417 to $5.2412, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote.